CSL Ltd
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $86.44
- Today's High:
- $87.19
- Open Price:
- $86.613
- 52W Low:
- $83.9953
- 52W High:
- $108.8519
- Prev. Close:
- $86.08
- Volume:
- 116042
Company Statistics
- Market Cap.:
- $99.68 billion
- Book Value:
- 16.254
- Revenue TTM:
- $11.70 billion
- Operating Margin TTM:
- 25.39%
- Gross Profit TTM:
- $5.73 billion
- Profit Margin:
- 18.09%
- Return on Assets TTM:
- 6.31%
- Return on Equity TTM:
- 13.38%
Company Profile
CSL Ltd had its IPO on under the ticker symbol CSLLY.
The company operates in the Healthcare sector and Biotechnology industry. CSL Ltd has a staff strength of 30,000 employees.
Stock update
Shares of CSL Ltd opened at $86.61 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $86.44 - $87.19, and closed at $86.63.
This is a +0.64% increase from the previous day's closing price.
A total volume of 116,042 shares were traded at the close of the day’s session.
In the last one week, shares of CSL Ltd have slipped by -1.02%.
CSL Ltd's Key Ratios
CSL Ltd has a market cap of $99.68 billion, indicating a price to book ratio of 6.77 and a price to sales ratio of 9.039.
In the last 12-months CSL Ltd’s revenue was $11.70 billion with a gross profit of $5.73 billion and an EBITDA of $3.45 billion. The EBITDA ratio measures CSL Ltd's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, CSL Ltd’s operating margin was 25.39% while its return on assets stood at 6.31% with a return of equity of 13.38%.
In Q2, CSL Ltd’s quarterly earnings growth was a negative -12.5% while revenue growth was a positive 18.9%.
CSL Ltd’s PE and PEG Ratio
- Forward PE
- 44.0529
- Trailing PE
- 47.8333
- PEG
- 0
Its diluted EPS in the last 12-months stands at $2.16 per share while it has a forward price to earnings multiple of 44.0529 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into CSL Ltd’s profitability.
CSL Ltd stock is trading at a EV to sales ratio of 9.2104 and a EV to EBITDA ratio of 27.8928. Its price to sales ratio in the trailing 12-months stood at 9.039.
CSL Ltd stock pays annual dividends of $2.25 per share, indicating a yield of 1.1% and a payout ratio of 51.39%.
Balance sheet and cash flow metrics
- Total Assets
- $28.35 billion
- Total Liabilities
- $7.11 billion
- Operating Cash Flow
- $-541350000.00
- Capital Expenditure
- $276.90 million
- Dividend Payout Ratio
- 51.39%
CSL Ltd ended 2024 with $28.35 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $28.35 billion while shareholder equity stood at $14.58 billion.
CSL Ltd ended 2024 with $0 in deferred long-term liabilities, $7.11 billion in other current liabilities, 483800000.00 in common stock, $13.50 billion in retained earnings and $1.19 billion in goodwill. Its cash balance stood at $10.44 billion and cash and short-term investments were $10.44 billion. The company’s total short-term debt was $4,494,000,000 while long-term debt stood at $3.86 billion.
CSL Ltd’s total current assets stands at $16.46 billion while long-term investments were $402.90 million and short-term investments were $0. Its net receivables were $1.48 billion compared to accounts payable of $591.80 million and inventory worth $4.33 billion.
In 2024, CSL Ltd's operating cash flow was $-541350000.00 while its capital expenditure stood at $276.90 million.
Comparatively, CSL Ltd paid $0.51 in dividends in 2024.
Other key metrics
- Current Trading Price
- $86.63
- 52-Week High
- $108.8519
- 52-Week Low
- $83.9953
- Analyst Target Price
- $
CSL Ltd stock is currently trading at $86.63 per share. It touched a 52-week high of $108.8519 and a 52-week low of $108.8519. Analysts tracking the stock have a 12-month average target price of $.
Its 50-day moving average was $87.08 and 200-day moving average was $95.9 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 0% of the company’s stock are held by insiders while 7.4% are held by institutions.
Frequently Asked Questions About CSL Ltd
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and CSL Seqirus. The CSL Behring segment offers plasma therapies, such as plasma products and recombinants. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The CSL Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza related products. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.